Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06828796
PHASE2
Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
Sponsor: Northside Hospital, Inc.
View on ClinicalTrials.gov
Summary
To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-07-03
Completion Date
2028-06-30
Last Updated
2025-10-30
Healthy Volunteers
No
Interventions
DRUG
Tacrolimus
Begins Day -1 and continues to Day +90 or Day +180 after transplant
DRUG
Cyclophosphamide
Given Days +3 and +4 after transplant
DRUG
Mycofenolate mofetil
Given Day 0 to Day +35 after transplant
Locations (1)
Northside Hospital
Atlanta, Georgia, United States